Residential areas in urban agglomerations and also in the countryside are often burdened with high concentrations of aerosol in winter, this originating from local combustion sources. Aerosol sources can be identified by a monitoring of organic markers of biomass burning. Abundant markers of biomass and softwood burning are levoglucosan and dehydroabietic acid, respectively. The aim of this research was to develop an analytical method for the determination of levoglucosan and dehydroabietic acid in aerosol over short time periods involving aerosol sampling into liquid samples, quantitative pre-concentration of analytes, and their determination by liquid chromatography - mass spectrometry. A Condensation Growth Unit - Aerosol Counterflow Two-Jets Unit (CGU-ACTJU) sampler was used for the quantitative collection of aerosol directly into water. Dehydroabietic acid was pre-concentrated from the aqueous phase by solid phase extraction (C-18). Afterwards, levoglucosan in water samples was concentrated on a vacuum evaporator. The detection limits of levoglucosan and dehydroabietic acid were 28 ng m-3 and 5.5 ng m-3, respectively. The results obtained by the developed method were compared with an independent determination of both markers in aerosol by means of the sampling of aerosols on a filter and subsequent analysis by GC-MS. The developed method demonstrated sufficient agreement with the independent determination for generated standard aerosol as well as for urban aerosol over an eight-day winter campaign. The presented method allows the monitoring of concentration changes in biomass burning markers in 2-h intervals.
BACKGROUND: There are limited data on systemic delivery of metabolic substrates during citrate anticoagulation. The direct citrate measurements are usually not available. METHODS: Patients on 2.2% acid-citrate-dextrose (ACD, n = 41) were compared to a control group on unfractionated heparin (n = 17). All were treated on 1.9-m(2) polysulfone filters. Samples were taken from the central venous catheter, ports pre- and post-filter and from effluent. RESULTS: The gain of citrate in CVVH (n = 18) was not different from CVVHDF (n = 23, p = 0.8). Mean gain of citrate was 25.4 ± 6.4 mmol/h. The systemic loads of lactate (p = 0.12) and glucose (p = 0.23) in CVVH were similar to CVVHDF. Mean inputs of lactate and glucose were 62.9 ± 21.1 and 26.6 ± 10.4 mmol/h, respectively. The mean difference between post- and prefilter unmeasured anions (d-UA) correlated with mean difference of citrate concentrations (p < 0.0001, r(2) = 0.66). The estimated caloric load of the citrate modalities was 5,536 ± 1,385 kJ/ 24 h. CONCLUSIONS: ACD might represent a significant load of metabolic substrates, particularly if used with lactate buffer. Systemic delivery of citrate can be predicted using d-UA in the extracorporeal circuit.
- MeSH
- akutní poškození ledvin terapie MeSH
- antikoagulancia metabolismus terapeutické užití MeSH
- design vybavení MeSH
- glukosa analogy a deriváty metabolismus terapeutické užití MeSH
- heparin terapeutické užití MeSH
- kyselina citronová metabolismus terapeutické užití MeSH
- kyselina mléčná metabolismus MeSH
- lidé MeSH
- náhrada funkce ledvin přístrojové vybavení metody MeSH
- prospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- srovnávací studie MeSH
Mixtures of ibandronate monosodium salt with eleven gluco- and/or galacto-pyranoside derivatives as counterions were designed to prepare co-crystals with improved intestinal absorption. In general, gastrointestinal absorption of bisphosphonates after oral administration is approximately 1%. Co-crystals were generated by means of thermodynamically and/or kinetically controlled crystallization processes. Seventy-seven prepared samples were analyzed by means of FT-NIR, FT-Raman spectrometry and solid state NMR spectroscopy. New entities of ibandronate monosodium salt with phenyl-β-D-galactopyranoside were found and characterized. The absorption of these potential new co-crystals was investigated by means of PAMPA experiments. In the present study the relationships between the chemical structures of the studied compounds required for co-crystal generation are discussed.
The crystal structures of a complete series of configurational isomers of 2,3-epimino and 3,4-epimino derivatives of 1,6-anhydro-β-D-hexopyranoses were determined by single-crystal X-ray analysis. The structures exhibited conformational rigidity within the series regardless of the position and orientation of the aziridine ring. Possible formation of intramolecular hydrogen bonds involving the NH group is discussed with respect to the results of IR spectroscopy and to the intermolecular hydrogen bonds found in the crystal packing.
Twelve positional isomers of diamino pseudodisaccharide derivatives with gluco-gluco configuration have been prepared using aziridine-ring cleavage of epimino derivatives of 1,6-anhydro-beta-D-hexopyranoses of the D-allo, D-manno, and D-galacto configuration by 2-, 3-, and 4-amino derivatives of 1,6-anhydro-beta-D-glucopyranose. The N-substitution of the aziridine ring by a 2-nitrobenzenesulfonyl group and ionic-liquid solvent (N-methylpyridinium tosylate) was used to obtain cleavage products in high yield (64-93%). The cleavage reactions proceeded according to the Fürst-Plattner rule and only trans-diaxial stereoisomers were formed.
- MeSH
- aminocukry chemická syntéza chemie MeSH
- aziridiny chemie MeSH
- financování organizované MeSH
- galaktosa analogy a deriváty chemie MeSH
- glukosa analogy a deriváty chemie MeSH
- hexosy chemie MeSH
- konformace sacharidů MeSH
- magnetická rezonanční spektroskopie MeSH
- mannosa analogy a deriváty chemie MeSH
- molekulární struktura MeSH
- sacharidové sekvence MeSH
- stereoizomerie MeSH
BACKGROUND: Somatostatin analogues labelled with radiometals or radiohalogens are useful for the imaging and treatment of somatostatin receptor-containing tumours. In this study, the procedures for the radioiodination of glucose-Tyr3-octreotate (gluc-Tyr3-tate) and radiolabelling of DOTA-Tyr3-octreotate (DOTA-Tyr3-tate) with 111In, 177Lu and 125I were compared and their metabolism in rats was analyzed. The usefulness of high performance liquid chromatography (HPLC) analysis and instant thin-layer chromatography on silica gel (ITLC-SG) for both radiochemical purity determination and analysis of metabolism in urine was investigated. MATERIALS AND METHODs: For labelling with radiometals, the formation of a complex with the 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) functionality of the peptide was employed. Radioiodination was performed by the chloramime-T method. The radiochemical purity of radiolabelled peptides and the analyses of rat urine were determined by HPLC and/or ITLC-SG methods. Male Wistar rats were used in the elimination studies. RESULTS: DOTA-Tyr3-tate was simply radiolabelled with radiometals with high yield and high radiochemical purity. Stopping of the reaction was a critical step for radioiodination, therefore labelling of gluc-Tyr3-tate and DOTA-Tyr3-tate with 125I was not so simple and the reaction product had to be purified by preparative HPLC analysis. Whereas 111In-DOTA-Tyr3-tate and 177Lu-DOTA-Tyr3-tate were eliminated in rat urine in a practically unchanged form, a significant proportion of metabolites was observed with radioiodinated peptides, particularly at longer time intervals. CONCLUSION: Labelling of DOTA-Tyr3-tate with radiometals is simple and the radiochemical purity of prepared compounds is very high, while iodination of the peptides demands purification of the product by preparative HPLC. The analysis of rat urine showed that excretion of radioiodinated peptides included a significant proportion of metabolites.
- MeSH
- cyklické peptidy chemie metabolismus MeSH
- financování organizované MeSH
- glukosa analogy a deriváty metabolismus MeSH
- heterocyklické sloučeniny monocyklické chemie metabolismus MeSH
- izotopové značení MeSH
- krevní proteiny metabolismus MeSH
- krysa rodu rattus MeSH
- lutecium chemie MeSH
- potkani Wistar MeSH
- radiofarmaka chemická syntéza metabolismus MeSH
- radioizotopy india chemie MeSH
- radioizotopy jodu chemie MeSH
- radionuklidy chemie MeSH
- vazba proteinů MeSH
- vysokoúčinná kapalinová chromatografie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- srovnávací studie MeSH
BACKGROUND: The efficacy and safety of prostacyclin (PGI2) and citrate (ACD) anticoagulation were observed and compared during continuous haemodiafiltration. METHODS: Mechanically ventilated patients received either the PGI2 analogue epoprostenol (group A, n = 17) in escalating doses of 4.5-10.0 ng.kg(-1).min(-1) in combination with heparin (6 IU.kg(-1).h(-1)) or 2.2% ACD (group B, n = 15). Blood flow was set to match the circuit-filling volume per unit time equal to the intravascular half-life of PGI2. RESULTS: Median filter lifetimes were 26 h (interquartile range 16-37) in group A (39 filters) and 36.5 h (interquartile range 23-50) in group B (56 filters; p < 0.01). In group A, 4 patients (23.5%, p < 0.05) had the dose reduced due to hypotension. The final mean dose of PGI2 was 8.7 +/- 2.4 ng.kg(-1).min(-1). Four patients in group A (23.5%, p < 0.05) were switched to ACD due to a decrease in platelet count. No bleeding episodes, decrease in platelet count or adverse haemodynamic effects were encountered in group B. The cost of epoprostenol plus low dose heparin (EUR 204.73 +/- 53.04) was significantly higher than the cost of ACD-based anticoagulation (EUR 93.92 +/- 45.2, p < 0.05). CONCLUSION: ACD offers longer filter survival, has no impact on platelet count and is less expensive. Increasing the dose of PGI2 up to the average of 8.7 ng.kg(-1).min(-1) did not increase the haemodynamic side effects. (c) 2005 S. Karger AG, Basel
- MeSH
- antikoagulancia aplikace a dávkování ekonomika MeSH
- epoprostenol aplikace a dávkování ekonomika MeSH
- glukosa analogy a deriváty aplikace a dávkování MeSH
- hemodiafiltrace metody normy MeSH
- heparin aplikace a dávkování MeSH
- krvácení prevence a kontrola MeSH
- kyselina citronová aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- riziko MeSH
- senioři MeSH
- trombocyty účinky léků MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- srovnávací studie MeSH
